Eisai Clinical Trials

An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Previously Treated Subjects With Advanced or Metastatic Soft Tissue Sarcoma

E7389-J081-217

Study Overview

E7389
eribulin mesilate
NCT01458249
Nov 2011 - Nov 2014
Soft Tissue Sarcoma
Progression-free rate (PFR)

  • Males and females (age 20 and over)

  • Completed

  • Phase 2

  • Japan

Results

CSR Synopsis

Download PDF

Lay Summary

No download available

Publication reference citation

Kawai A, et al. Phase 2 study of eribulin in patients with previously treated advanced or metastatic soft tissue sarcoma. Jpn J Clin Oncol 2017 02;47(2):137-144. DOI: 10.1093/jjco/hyw175

Data Sharing

ClinicalStudyDataRequest.com (CSDR) is a multi sponsor site through which qualified researchers who wish to access clinical trial data and associated information in order to conduct further research can submit their research proposal or enquiry.

Redacted documents are available upon request for this study.

Document type Availability
Protocol
SAP
Sample CRF
Full CSR